880P Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial.
Saved in:
| Title: | 880P Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial. |
|---|---|
| Authors: | Fuereder, T.1 (AUTHOR), Klinghammer, K.2 (AUTHOR), Hahn, D.A.3 (AUTHOR), Grünberger, B.4 (AUTHOR), Melchardt, T.5 (AUTHOR), Greil, R.5 (AUTHOR), Kocher, F.6 (AUTHOR), Gamerith, G.6 (AUTHOR), Wagner, C.1 (AUTHOR), Berchtold, L.1 (AUTHOR), Burian, M.7 (AUTHOR), Strobl, A.7 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS629-S629. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 179692337 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 880P Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Fuereder%2C+T%2E%22">Fuereder, T.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Klinghammer%2C+K%2E%22">Klinghammer, K.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hahn%2C+D%2EA%2E%22">Hahn, D.A.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Grünberger%2C+B%2E%22">Grünberger, B.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Melchardt%2C+T%2E%22">Melchardt, T.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Greil%2C+R%2E%22">Greil, R.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kocher%2C+F%2E%22">Kocher, F.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gamerith%2C+G%2E%22">Gamerith, G.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wagner%2C+C%2E%22">Wagner, C.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Berchtold%2C+L%2E%22">Berchtold, L.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Burian%2C+M%2E%22">Burian, M.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Strobl%2C+A%2E%22">Strobl, A.</searchLink><relatesTo>7</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2024 Supplement 2, Vol. 35, pS629-S629. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=179692337 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2024.08.941 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S629 Titles: – TitleFull: 880P Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Fuereder, T. – PersonEntity: Name: NameFull: Klinghammer, K. – PersonEntity: Name: NameFull: Hahn, D.A. – PersonEntity: Name: NameFull: Grünberger, B. – PersonEntity: Name: NameFull: Melchardt, T. – PersonEntity: Name: NameFull: Greil, R. – PersonEntity: Name: NameFull: Kocher, F. – PersonEntity: Name: NameFull: Gamerith, G. – PersonEntity: Name: NameFull: Wagner, C. – PersonEntity: Name: NameFull: Berchtold, L. – PersonEntity: Name: NameFull: Burian, M. – PersonEntity: Name: NameFull: Strobl, A. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2024 Supplement 2 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 35 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |